At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 214 enrolled
Drug / intervention
Pitavastatin +1 moredrug
Likely dose
Pitavastatin 4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Double-Blind, Follow-On Study of Pitavastatin (4 mg) Versus Atorvastatin (20 mg and 40 mg), With a Single-Blind Extension of Treatment, in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia
In Brief
A Phase 3 clinical trial evaluating Pitavastatin and Atorvastatin for Type II Diabetes Mellitus and Dyslipidemia. Completed, enrolled 214 participants across 35 sites in 6 countries.
Detailed Summary
This is a sixteen-week double-blind active-controlled follow-on and 28-week single-blind extension study for patients who participated in study NK-104-305.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType II Diabetes Mellitus, Dyslipidemia
CountriesDenmark, Germany, India, Netherlands, Poland, United Kingdom
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 2006
Enrollment StartAug 2006
Primary CompletionApr 2008
TodayJul 2026
First PostedJun 26, 2006
Enrollment StartAug 1, 2006
Primary CompletionApr 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 20.0 years ago
Interventions
Pitavastatindrug
Pitavastatin 4 mg QD
Atorvastatindrug
Atorvastatin 40 mg